9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the...
Saved in:
| Published in | Diabetes care Vol. 44; no. Supplement_1; pp. S111 - S124 |
|---|---|
| Format | Journal Article |
| Language | English |
| Published |
Alexandria
American Diabetes Association
01.01.2021
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc21-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc21-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC. |
|---|---|
| AbstractList | The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc21-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc21-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc21-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc21-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC. The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc21-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc21-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC. |
| BookMark | eNptkM1KxDAQgIMouP4cfIOAFz1UkybZNt5k_QVFYddzmSZTjbTNmmQP3nwIn9AnMYuexNPA8M3w8e2QzdGPSMgBZyelENWpNSUv5ozpDTLhWqhCKVlvkgnjUhdK63Kb7MT4yhiTsq4npNEn9PEFwgDG9_7ZGXq-XAYP5gUjTZ5e9-8Gh7xeBIQ04JjO6DzBaCHYSH1H79E6Az2dQUDqRnrhoMWE8evjs2Ql3yNbHfQR93_nLnm6ulzMboq7h-vb2fldYcp6mopWZ82pFgYrka25kmihrayRdSWMqk2nmWStQCE1lGiVlQK6quNW19gKELvk6Odvln9bYUzN4KLBvocR_So2pZxqpqXSVUYP_6CvfhXGbJepeso1U5XM1PEPZYKPMWDXLIMbILw3nDXr1M06dbNOndnTP6xxCZLzYwrg-n8uvgGMToHz |
| CitedBy_id | crossref_primary_10_2337_dc24_1903 crossref_primary_10_1007_s13300_021_01045_7 crossref_primary_10_3389_fpubh_2022_852721 crossref_primary_10_1007_s13300_022_01270_8 crossref_primary_10_3390_medicina58081061 crossref_primary_10_1016_j_metabol_2021_154799 crossref_primary_10_7759_cureus_42775 crossref_primary_10_3390_s23115003 crossref_primary_10_2337_cd21_0066 crossref_primary_10_1186_s12916_023_02906_7 crossref_primary_10_1007_s40619_022_01064_x crossref_primary_10_1016_j_diabres_2021_108931 crossref_primary_10_1001_jamanetworkopen_2022_1169 crossref_primary_10_1371_journal_pone_0273836 crossref_primary_10_3390_medicina59101760 crossref_primary_10_2147_DMSO_S223618 crossref_primary_10_1111_1750_3841_15939 crossref_primary_10_1007_s13300_021_01034_w crossref_primary_10_1186_s12902_024_01798_9 crossref_primary_10_1007_s13300_022_01282_4 crossref_primary_10_1186_s13643_022_02108_x crossref_primary_10_1515_jom_2022_0251 crossref_primary_10_1007_s13300_021_01189_6 crossref_primary_10_1016_j_diabres_2022_110183 crossref_primary_10_2337_cd21_0078 crossref_primary_10_1016_j_bcp_2021_114413 crossref_primary_10_22237_crp_1622160600 crossref_primary_10_24304_kjcp_2022_32_1_13 crossref_primary_10_3389_fnut_2021_690855 crossref_primary_10_3390_molecules26092408 crossref_primary_10_3390_jcm13092582 crossref_primary_10_15406_emij_2021_09_00305 crossref_primary_10_1039_D1FO03620C crossref_primary_10_2337_ds22_0031 crossref_primary_10_33667_2078_5631_2022_13_44_47 crossref_primary_10_2196_34561 crossref_primary_10_3389_fmolb_2022_971768 crossref_primary_10_3390_biom11121834 crossref_primary_10_1111_jdi_13915 crossref_primary_10_1186_s12875_022_01731_w crossref_primary_10_15406_jdmdc_2021_08_00223 crossref_primary_10_26693_jmbs07_01_014 crossref_primary_10_3390_medicina57070669 crossref_primary_10_1016_j_hfc_2022_03_001 crossref_primary_10_1111_jcpt_13528 crossref_primary_10_2337_cd21_0083 crossref_primary_10_1186_s12882_024_03808_3 crossref_primary_10_1007_s10389_022_01769_1 crossref_primary_10_1007_s13300_024_01604_8 crossref_primary_10_1016_j_metabol_2021_154890 crossref_primary_10_1515_jbcpp_2021_0189 crossref_primary_10_4239_wjd_v15_i8_1778 crossref_primary_10_1002_jac5_1544 crossref_primary_10_1177_19322968221104142 crossref_primary_10_3390_nu14020320 crossref_primary_10_7570_jomes22001 crossref_primary_10_2337_dc21_1815 crossref_primary_10_17476_jmbs_2022_11_2_13 crossref_primary_10_1038_s41598_023_28138_6 crossref_primary_10_2174_1573399818666220516105920 crossref_primary_10_7759_cureus_17668 crossref_primary_10_1002_sfp2_1006 crossref_primary_10_1126_sciadv_ads5466 crossref_primary_10_2337_cd21_0096 crossref_primary_10_3389_fphar_2023_1143928 crossref_primary_10_1016_j_cca_2023_117516 crossref_primary_10_1186_s12875_021_01615_5 crossref_primary_10_1007_s13300_022_01218_y crossref_primary_10_2337_dc22_1253 crossref_primary_10_1007_s40620_023_01858_8 crossref_primary_10_3390_ijms251910828 crossref_primary_10_1007_s00774_022_01372_0 crossref_primary_10_1071_HC21122 crossref_primary_10_1007_s13300_023_01421_5 crossref_primary_10_59294_HIUJS_29_2024_614 crossref_primary_10_2337_dci21_0051 crossref_primary_10_1177_10742484231162248 crossref_primary_10_1186_s13098_021_00775_9 crossref_primary_10_14814_phy2_15151 crossref_primary_10_14797_mdcvj_1120 crossref_primary_10_3390_cancers14010089 crossref_primary_10_1016_j_jdiacomp_2023_108541 crossref_primary_10_14341_DM12774 crossref_primary_10_1007_s13340_021_00560_z crossref_primary_10_1080_14656566_2021_1985465 crossref_primary_10_5348_100073Z09HW2022CS crossref_primary_10_2217_cer_2021_0232 crossref_primary_10_1177_14791641221106866 crossref_primary_10_3389_fmed_2022_995993 crossref_primary_10_3390_jpm11121249 crossref_primary_10_2147_DMSO_S468070 crossref_primary_10_36290_far_2021_027 crossref_primary_10_1007_s12325_022_02138_w crossref_primary_10_1371_journal_pone_0314287 crossref_primary_10_1177_08971900211039707 crossref_primary_10_1007_s11606_024_08793_9 crossref_primary_10_3390_pharmacy9040186 crossref_primary_10_2337_ds22_0042 crossref_primary_10_1016_j_mmm_2021_09_008 crossref_primary_10_3389_fendo_2021_779636 crossref_primary_10_3390_healthcare10071153 crossref_primary_10_1136_bmjebm_2022_112067 crossref_primary_10_1111_dme_14858 crossref_primary_10_1016_j_clinthera_2022_04_005 crossref_primary_10_1186_s13223_023_00761_y crossref_primary_10_3389_fendo_2021_664533 crossref_primary_10_4330_wjc_v16_i8_448 crossref_primary_10_1007_s13300_022_01358_1 crossref_primary_10_1016_j_phrs_2021_105819 crossref_primary_10_1016_j_biopha_2021_112393 crossref_primary_10_1007_s40292_021_00479_1 crossref_primary_10_4239_wjd_v13_i12_1014 crossref_primary_10_1080_07853890_2021_1925148 crossref_primary_10_1007_s00592_023_02045_8 crossref_primary_10_7326_M21_0893 crossref_primary_10_36628_ijhf_2021_0039 crossref_primary_10_1080_17512433_2022_2053111 crossref_primary_10_55204_trc_v9789i8788_48 crossref_primary_10_2337_dc21_1744 crossref_primary_10_1038_s41598_024_55313_0 crossref_primary_10_3390_ijms25063086 crossref_primary_10_1016_j_talanta_2021_122442 crossref_primary_10_1002_phar_2527 crossref_primary_10_1002_phar_2648 crossref_primary_10_1080_14656566_2021_1967931 crossref_primary_10_1016_j_diabres_2021_109096 crossref_primary_10_1097_MLR_0000000000001696 crossref_primary_10_3390_jcm11185435 crossref_primary_10_1002_oby_24172 crossref_primary_10_1016_j_diabres_2023_110884 crossref_primary_10_1007_s13300_022_01302_3 crossref_primary_10_2337_dci20_0076 crossref_primary_10_1016_j_pec_2021_07_036 crossref_primary_10_1016_j_pcd_2022_03_012 crossref_primary_10_3390_metabo11020073 crossref_primary_10_4239_wjd_v13_i12_1168 crossref_primary_10_7326_M21_2941 crossref_primary_10_2169_naika_110_2458 crossref_primary_10_3389_fendo_2023_1218880 crossref_primary_10_3389_fphar_2022_918681 crossref_primary_10_1186_s12933_022_01619_0 crossref_primary_10_1515_jom_2023_0179 crossref_primary_10_2967_jnumed_122_265248 crossref_primary_10_3389_fphar_2021_726490 crossref_primary_10_1136_bmjdrc_2021_002496 crossref_primary_10_1007_s12325_022_02366_0 crossref_primary_10_1001_jamanetworkopen_2022_41505 crossref_primary_10_1007_s43440_021_00289_1 crossref_primary_10_3748_wjg_v28_i25_2881 crossref_primary_10_23736_S0031_0808_21_04540_7 crossref_primary_10_1039_D1FO02788C crossref_primary_10_1007_s11606_021_07227_0 crossref_primary_10_51847_RgpUP8AeB3 crossref_primary_10_2147_DDDT_S281602 crossref_primary_10_2337_cd20_0117 crossref_primary_10_1097_EDE_0000000000001486 crossref_primary_10_1007_s11886_021_01546_8 crossref_primary_10_1007_s40256_023_00572_x crossref_primary_10_1021_acs_jnatprod_1c00785 crossref_primary_10_1016_j_jdiacomp_2021_108075 crossref_primary_10_1016_j_phrs_2021_105836 crossref_primary_10_2337_cd20_0121 crossref_primary_10_17352_2455_2283_000103 crossref_primary_10_2147_DMSO_S312527 crossref_primary_10_1016_j_jdiacomp_2021_108077 crossref_primary_10_1016_j_jdiacomp_2022_108255 crossref_primary_10_1016_j_jcin_2021_03_006 crossref_primary_10_14341_DM12768 crossref_primary_10_26442_00403660_2021_10_201070 crossref_primary_10_1186_s12890_021_01667_4 crossref_primary_10_1016_j_mmm_2022_01_004 crossref_primary_10_1007_s13300_023_01462_w crossref_primary_10_36290_vnl_2021_108 crossref_primary_10_3389_fendo_2022_880164 crossref_primary_10_1016_j_repce_2021_11_017 crossref_primary_10_1016_j_diabres_2023_111034 crossref_primary_10_1111_bcp_15711 crossref_primary_10_3390_cancers14184402 crossref_primary_10_1002_dmrr_3503 crossref_primary_10_2196_34624 crossref_primary_10_1210_endrev_bnac021 crossref_primary_10_2217_fca_2021_0028 crossref_primary_10_1111_dom_14710 crossref_primary_10_1111_dom_14831 crossref_primary_10_1002_ehf2_14213 crossref_primary_10_1016_j_cardfail_2022_10_426 crossref_primary_10_1007_s13300_022_01226_y crossref_primary_10_1007_s13340_021_00508_3 crossref_primary_10_2337_dci23_0030 crossref_primary_10_3390_ijerph20054036 crossref_primary_10_54718_LAKR5242 crossref_primary_10_1038_s41598_022_09627_6 crossref_primary_10_1007_s12325_021_01989_z crossref_primary_10_1177_15269248221122869 crossref_primary_10_1001_jamanetworkopen_2022_40117 crossref_primary_10_3390_biomedicines9070745 crossref_primary_10_1007_s11010_022_04374_8 crossref_primary_10_2337_dc22_2395 crossref_primary_10_1177_2633559X211068884 crossref_primary_10_1007_s11892_021_01434_z crossref_primary_10_1016_j_diabres_2023_111045 crossref_primary_10_1111_dom_14606 crossref_primary_10_2147_DMSO_S315227 crossref_primary_10_1016_j_repc_2021_07_009 crossref_primary_10_22516_25007440_979 crossref_primary_10_3390_pharmaceutics16121607 crossref_primary_10_1186_s12933_023_01736_4 crossref_primary_10_1111_iwj_14370 crossref_primary_10_22141_2224_0721_17_8_2021_246799 crossref_primary_10_17816_KMJ2021_206 crossref_primary_10_2174_1573402117666210406111927 crossref_primary_10_1016_j_cyto_2021_155549 crossref_primary_10_3389_fphar_2022_919881 crossref_primary_10_3390_biom13081199 crossref_primary_10_7759_cureus_65707 crossref_primary_10_1001_jamainternmed_2021_2487 crossref_primary_10_1002_cpt_2975 crossref_primary_10_1016_j_ijcard_2021_02_035 crossref_primary_10_17352_2455_5282_000142 crossref_primary_10_1007_s40670_021_01395_8 crossref_primary_10_1111_dom_14932 crossref_primary_10_3390_nu13051708 crossref_primary_10_1007_s13300_022_01300_5 crossref_primary_10_1007_s40273_023_01268_5 crossref_primary_10_36290_vnl_2022_018 crossref_primary_10_18231_j_ctppc_2023_026 crossref_primary_10_1007_s13300_022_01225_z crossref_primary_10_1093_ndt_gfac140 crossref_primary_10_1080_14656566_2022_2089021 crossref_primary_10_3390_ph14100991 crossref_primary_10_1080_14656566_2021_1999413 crossref_primary_10_1007_s13300_022_01247_7 crossref_primary_10_3390_ijms222111463 crossref_primary_10_1097_MD_0000000000034027 crossref_primary_10_9778_cmajo_20210281 crossref_primary_10_23736_S2724_5683_22_05967_1 crossref_primary_10_3390_biomedicines11020322 crossref_primary_10_1038_s41598_021_86001_y crossref_primary_10_1038_s41598_024_84993_x crossref_primary_10_1080_23808993_2021_1970526 crossref_primary_10_36469_jheor_2024_92368 crossref_primary_10_1002_cpdd_1310 crossref_primary_10_3390_jpm12030454 crossref_primary_10_1515_jbcpp_2023_0003 crossref_primary_10_14283_jpad_2023_113 crossref_primary_10_3390_cells10081958 crossref_primary_10_3390_jcm10092013 crossref_primary_10_1016_j_healun_2022_07_011 crossref_primary_10_1186_s12875_022_01889_3 crossref_primary_10_1007_s12325_022_02121_5 crossref_primary_10_7748_ns_2023_e11997 crossref_primary_10_1007_s43450_023_00460_0 crossref_primary_10_1007_s11517_022_02602_3 crossref_primary_10_1186_s12933_021_01386_4 crossref_primary_10_1111_dom_14518 crossref_primary_10_1016_j_jmgm_2024_108938 crossref_primary_10_1111_dom_14513 crossref_primary_10_3389_fmed_2021_712671 crossref_primary_10_3389_fendo_2022_836365 crossref_primary_10_1016_j_pcd_2024_05_001 crossref_primary_10_1016_j_diabres_2021_108737 crossref_primary_10_1016_j_jdiacomp_2021_107975 crossref_primary_10_1007_s13300_022_01320_1 crossref_primary_10_1016_j_diabet_2021_101315 crossref_primary_10_1371_journal_pone_0299484 crossref_primary_10_1007_s43440_021_00347_8 crossref_primary_10_1016_j_diabres_2024_111745 crossref_primary_10_1007_s10549_022_06798_8 crossref_primary_10_1038_s41598_024_52078_4 crossref_primary_10_1007_s13300_022_01269_1 crossref_primary_10_1016_j_jemep_2023_100890 crossref_primary_10_1007_s12325_021_01985_3 crossref_primary_10_1111_dom_14769 crossref_primary_10_2337_dc23_1791 crossref_primary_10_1016_j_med_2021_12_003 crossref_primary_10_1186_s12933_022_01581_x crossref_primary_10_3390_endocrines2040047 crossref_primary_10_3390_healthcare11020238 crossref_primary_10_3928_00989134_20210908_02 crossref_primary_10_4239_wjd_v15_i7_1477 crossref_primary_10_1111_dom_14881 crossref_primary_10_3390_ph17070898 crossref_primary_10_1038_s41467_022_34754_z crossref_primary_10_1210_clinem_dgac277 crossref_primary_10_1111_dom_14642 crossref_primary_10_1111_dom_14764 crossref_primary_10_3389_fendo_2022_1072879 crossref_primary_10_1007_s40618_022_01788_5 crossref_primary_10_1080_00015385_2022_2076307 crossref_primary_10_2337_db22_0702 crossref_primary_10_2337_dc21_0393 crossref_primary_10_1002_edm2_330 crossref_primary_10_3390_jcm12051981 crossref_primary_10_1016_j_jdiacomp_2021_107949 crossref_primary_10_2147_DMSO_S367153 crossref_primary_10_1002_edm2_319 crossref_primary_10_1177_2633559X221093294 crossref_primary_10_2337_dc21_0013 crossref_primary_10_1001_jamanetworkopen_2022_53562 crossref_primary_10_1001_jama_2021_12559 crossref_primary_10_1007_s11428_023_01024_5 crossref_primary_10_12793_tcp_2022_30_e23 crossref_primary_10_2147_DMSO_S373712 crossref_primary_10_1111_dom_14739 crossref_primary_10_3390_pharmacy10040079 crossref_primary_10_4239_wjd_v12_i12_2036 crossref_primary_10_1080_14740338_2021_1978974 crossref_primary_10_3390_ijms24119324 crossref_primary_10_3389_fendo_2021_738848 crossref_primary_10_12677_ACM_2023_132386 crossref_primary_10_2174_1573399819666230116150205 crossref_primary_10_3390_ph16050724 crossref_primary_10_1016_j_jacc_2021_11_027 crossref_primary_10_1016_j_diabres_2021_108958 crossref_primary_10_1053_j_ajkd_2023_01_446 crossref_primary_10_1080_14656566_2021_1959915 crossref_primary_10_1371_journal_pone_0298010 crossref_primary_10_1007_s11892_023_01504_4 crossref_primary_10_2174_1573399817666210820105514 crossref_primary_10_21518_2079_701X_2021_7_33_44 crossref_primary_10_1161_JAHA_122_028923 crossref_primary_10_1097_TP_0000000000003867 crossref_primary_10_1007_s13300_021_01180_1 crossref_primary_10_1111_dom_14868 crossref_primary_10_1007_s13300_021_01116_9 crossref_primary_10_1007_s13300_022_01222_2 crossref_primary_10_3389_fphar_2024_1501990 crossref_primary_10_1007_s11606_022_07621_2 crossref_primary_10_3349_ymj_2022_63_9_825 crossref_primary_10_3389_fimmu_2021_642166 crossref_primary_10_1016_j_diabres_2024_111763 crossref_primary_10_3390_molecules27196221 crossref_primary_10_3389_fphar_2022_925377 crossref_primary_10_1111_dom_15832 crossref_primary_10_1093_jncics_pkad017 crossref_primary_10_1111_dom_14500 crossref_primary_10_1016_j_diabres_2021_108823 crossref_primary_10_3389_fendo_2023_1316269 crossref_primary_10_1016_j_diabres_2021_108824 crossref_primary_10_1007_s13679_021_00444_y crossref_primary_10_1080_17446651_2023_2216279 crossref_primary_10_1080_14656566_2021_1912734 crossref_primary_10_2169_naika_110_1872 crossref_primary_10_1007_s11904_022_00600_6 crossref_primary_10_1186_s12933_021_01362_y crossref_primary_10_3390_life13051094 crossref_primary_10_1007_s40200_024_01388_5 crossref_primary_10_1126_science_abg4502 crossref_primary_10_1111_dom_14679 crossref_primary_10_2147_DMSO_S331654 crossref_primary_10_7759_cureus_48998 crossref_primary_10_1111_dom_14674 crossref_primary_10_2147_DMSO_S344607 crossref_primary_10_1111_dom_14799 crossref_primary_10_1016_j_ijcard_2023_03_015 crossref_primary_10_31083_j_rcm2402036 crossref_primary_10_3389_fphar_2022_1004617 crossref_primary_10_1136_bmjopen_2022_060786 crossref_primary_10_1055_s_0044_1782673 crossref_primary_10_1080_13543784_2021_1985463 crossref_primary_10_2147_PPA_S397647 crossref_primary_10_1177_10760296221083681 crossref_primary_10_3389_fcvm_2022_1075421 crossref_primary_10_3390_biomedicines9080936 crossref_primary_10_1007_s12529_023_10172_3 crossref_primary_10_1007_s00467_021_05347_7 crossref_primary_10_3389_fcvm_2021_785109 crossref_primary_10_3390_nu14030606 crossref_primary_10_1007_s13300_022_01267_3 crossref_primary_10_1177_10815589221149188 crossref_primary_10_21518_ms2023_211 crossref_primary_10_1080_14656566_2021_1980538 crossref_primary_10_1097_FJC_0000000000001099 crossref_primary_10_1111_dom_14684 crossref_primary_10_7326_M21_4012 crossref_primary_10_3390_plants11233224 crossref_primary_10_1002_hep4_1876 crossref_primary_10_1056_NEJMsa2032271 crossref_primary_10_1111_dom_14566 crossref_primary_10_3389_fphar_2022_991087 crossref_primary_10_1007_s13300_021_01182_z crossref_primary_10_1016_j_diabet_2022_101366 crossref_primary_10_3389_fphar_2024_1364110 crossref_primary_10_3390_jpm12111865 crossref_primary_10_3389_fendo_2021_810757 crossref_primary_10_46310_tjim_877156 crossref_primary_10_1016_j_dsx_2022_102528 crossref_primary_10_1007_s13300_021_01170_3 crossref_primary_10_1080_17446651_2022_2014322 crossref_primary_10_1136_bmj_2022_071380 crossref_primary_10_3389_fendo_2022_905171 crossref_primary_10_1080_17425255_2021_1921735 crossref_primary_10_1080_00325481_2022_2126235 crossref_primary_10_1111_dom_14537 crossref_primary_10_3390_ijms22115973 crossref_primary_10_7759_cureus_57241 crossref_primary_10_1111_dom_14414 crossref_primary_10_1016_j_foodres_2023_113689 crossref_primary_10_1111_dom_14533 crossref_primary_10_1161_JAHA_121_023489 crossref_primary_10_3892_etm_2021_10601 crossref_primary_10_1093_rheumatology_keac254 crossref_primary_10_1007_s13410_022_01049_4 crossref_primary_10_1016_j_diabet_2021_101283 crossref_primary_10_1016_j_mmm_2021_04_006 crossref_primary_10_1016_j_diabet_2021_101285 crossref_primary_10_1007_s12325_023_02442_z crossref_primary_10_2337_dc21_2105 crossref_primary_10_1016_j_deman_2022_100054 crossref_primary_10_2337_dc20_2541 crossref_primary_10_1515_tjb_2023_0022 crossref_primary_10_18553_jmcp_2023_29_3_276 crossref_primary_10_1038_s41574_022_00708_0 crossref_primary_10_3389_fcdhc_2023_1181729 crossref_primary_10_2147_PGPM_S271582 crossref_primary_10_1111_dom_14787 crossref_primary_10_1111_dom_14543 crossref_primary_10_1007_s40261_023_01255_w crossref_primary_10_1210_jendso_bvac010 crossref_primary_10_3389_fphar_2023_1303694 crossref_primary_10_1016_j_jacasi_2021_08_003 crossref_primary_10_2174_1389201023666220603092433 crossref_primary_10_1016_j_clinthera_2022_07_009 crossref_primary_10_1001_jamanetworkopen_2022_35995 crossref_primary_10_5114_amsad_2021_107817 crossref_primary_10_1016_j_lfs_2021_120026 crossref_primary_10_1186_s12933_024_02521_7 crossref_primary_10_2217_cer_2022_0110 crossref_primary_10_3389_fendo_2022_1091421 crossref_primary_10_1007_s11154_021_09675_9 crossref_primary_10_3390_pharmaceutics14061180 crossref_primary_10_1080_14656566_2021_1954160 crossref_primary_10_1161_CIRCULATIONAHA_121_057934 crossref_primary_10_1111_dom_14354 crossref_primary_10_1111_dom_15443 crossref_primary_10_1007_s12325_021_01921_5 crossref_primary_10_1038_s41581_024_00854_w crossref_primary_10_3390_antiox11122430 crossref_primary_10_1016_j_apnr_2021_151478 crossref_primary_10_1136_bmjmed_2022_000419 crossref_primary_10_1111_jdi_13786 crossref_primary_10_7759_cureus_25312 crossref_primary_10_1161_CIR_0000000000001040 crossref_primary_10_1016_j_mmm_2021_12_010 crossref_primary_10_1016_j_diabres_2022_109828 crossref_primary_10_1136_bmj_2023_078242 crossref_primary_10_2337_dc22_0714 crossref_primary_10_1111_dom_14593 crossref_primary_10_3390_metabo12020183 crossref_primary_10_1016_j_diabres_2022_109821 crossref_primary_10_3389_fcvm_2021_658059 crossref_primary_10_1007_s13300_022_01289_x crossref_primary_10_1186_s13741_023_00302_6 crossref_primary_10_3390_biom13030497 crossref_primary_10_3346_jkms_2021_36_e230 crossref_primary_10_1186_s43054_024_00311_0 crossref_primary_10_1111_dom_15219 crossref_primary_10_1177_23814683231187566 crossref_primary_10_1093_cvr_cvab271 crossref_primary_10_1001_jamanetworkopen_2021_30762 crossref_primary_10_1002_alz_14048 crossref_primary_10_1016_j_metabol_2021_154924 crossref_primary_10_1111_dom_14365 crossref_primary_10_1089_dia_2021_0001 crossref_primary_10_1111_dom_14488 crossref_primary_10_2147_JMDH_S292945 crossref_primary_10_1007_s11096_022_01464_x crossref_primary_10_1007_s13300_021_01184_x crossref_primary_10_2147_DMSO_S369712 crossref_primary_10_2337_dc20_2715 crossref_primary_10_4236_health_2021_1312102 crossref_primary_10_1007_s13410_023_01197_1 crossref_primary_10_1016_j_mmm_2021_12_004 crossref_primary_10_1016_j_jacc_2022_03_353 crossref_primary_10_1021_acs_jafc_1c07799 crossref_primary_10_1016_j_toxrep_2021_07_011 crossref_primary_10_3390_medicina58020293 crossref_primary_10_2169_internalmedicine_9179_21 crossref_primary_10_3390_ijms22189800 crossref_primary_10_1007_s10103_021_03434_7 crossref_primary_10_36502_2021_ASJBCCR_6233 crossref_primary_10_1080_13543784_2022_2159806 crossref_primary_10_1007_s11845_025_03916_5 crossref_primary_10_1080_14737167_2022_2044310 crossref_primary_10_1111_dom_14451 crossref_primary_10_1111_dom_14452 crossref_primary_10_3390_life12111736 crossref_primary_10_1001_jamanetworkopen_2021_28782 crossref_primary_10_1089_dia_2021_0277 crossref_primary_10_2337_dc20_2623 crossref_primary_10_1177_20420188221102800 crossref_primary_10_1111_dom_14691 crossref_primary_10_1136_bmjopen_2024_087498 crossref_primary_10_1177_19322968221098057 crossref_primary_10_1161_JAHA_120_024482 crossref_primary_10_1136_jim_2022_002480 crossref_primary_10_1111_acem_14895 crossref_primary_10_1080_10543406_2022_2058525 crossref_primary_10_1007_s13300_022_01264_6 crossref_primary_10_1007_s11606_021_07157_x crossref_primary_10_1111_dom_14349 crossref_primary_10_1016_j_biopha_2024_116631 crossref_primary_10_1007_s12325_022_02196_0 crossref_primary_10_1111_dom_14464 crossref_primary_10_2337_ds21_0095 crossref_primary_10_1111_jdi_13677 crossref_primary_10_1016_j_ejvs_2023_08_067 crossref_primary_10_1111_jdi_13799 crossref_primary_10_1007_s11892_021_01407_2 crossref_primary_10_1210_clinem_dgac333 crossref_primary_10_1111_dom_14469 crossref_primary_10_1177_2633559X221080161 crossref_primary_10_3389_fphar_2021_766125 crossref_primary_10_1056_NEJMoa2200433 crossref_primary_10_1016_j_diabres_2022_109937 crossref_primary_10_1016_j_mmm_2024_12_005 crossref_primary_10_3389_fmed_2021_777861 crossref_primary_10_7759_cureus_71739 crossref_primary_10_1016_j_endien_2021_11_028 crossref_primary_10_3390_biomedicines10102421 crossref_primary_10_1001_jamainternmed_2023_6663 crossref_primary_10_1093_ckj_sfac069 crossref_primary_10_2174_1574886317666220304124756 crossref_primary_10_1038_s41588_022_01200_1 crossref_primary_10_1161_JAHA_122_026297 crossref_primary_10_3390_ph15040442 crossref_primary_10_56782_pps_127 crossref_primary_10_1007_s40200_024_01406_6 crossref_primary_10_3389_fendo_2021_741114 crossref_primary_10_1016_j_diabres_2022_109231 crossref_primary_10_1111_dme_14780 crossref_primary_10_2337_dc20_2492 crossref_primary_10_1016_j_saa_2021_120298 crossref_primary_10_1155_2022_6197070 crossref_primary_10_1007_s00772_024_01086_9 crossref_primary_10_1016_j_biopha_2023_115515 crossref_primary_10_7759_cureus_21667 crossref_primary_10_1080_14779072_2022_2094771 crossref_primary_10_1097_XCE_0000000000000295 crossref_primary_10_1016_j_omtn_2022_12_009 crossref_primary_10_1016_j_atherosclerosis_2022_05_010 crossref_primary_10_1038_s41392_022_01073_0 crossref_primary_10_1111_jdi_13621 crossref_primary_10_3390_healthcare11081138 crossref_primary_10_3390_ph14111196 crossref_primary_10_1186_s12875_022_01928_z crossref_primary_10_1111_1753_0407_13266 crossref_primary_10_3390_ijms242015078 crossref_primary_10_1111_dom_14392 crossref_primary_10_1002_clc_23948 crossref_primary_10_1093_bjsopen_zrac169 crossref_primary_10_2147_DMSO_S321340 crossref_primary_10_3389_fendo_2021_613389 crossref_primary_10_1016_j_ijcard_2020_12_074 crossref_primary_10_1136_bmjdrc_2021_002590 crossref_primary_10_1016_j_diabres_2021_109067 crossref_primary_10_1515_jom_2021_0035 crossref_primary_10_3389_fphar_2021_787704 crossref_primary_10_1155_2022_6796470 crossref_primary_10_1136_bmj_n1091 crossref_primary_10_14341_DM12864 crossref_primary_10_3390_ijms22179454 crossref_primary_10_3390_jcm12010221 crossref_primary_10_1080_17512433_2022_2108402 crossref_primary_10_3389_fendo_2024_1395651 crossref_primary_10_1016_j_bbrc_2024_150403 crossref_primary_10_1080_17512433_2022_2108400 crossref_primary_10_1111_1753_0407_13254 crossref_primary_10_3390_ijms222312677 crossref_primary_10_1371_journal_pone_0294164 crossref_primary_10_2174_0118715303294909240221102552 crossref_primary_10_12820_rbafs_27e0271 crossref_primary_10_1111_bph_15819 crossref_primary_10_1111_dom_15011 crossref_primary_10_1136_bmjdrc_2021_002348 crossref_primary_10_3390_ijms23031884 crossref_primary_10_2337_db21_0777 crossref_primary_10_1042_BST20240262 crossref_primary_10_1080_17512433_2023_2161045 crossref_primary_10_1016_j_ijcard_2022_07_017 crossref_primary_10_1111_eci_13890 crossref_primary_10_2337_db23_0506 crossref_primary_10_3389_fmed_2022_813917 crossref_primary_10_36469_001c_92368 crossref_primary_10_1210_clinem_dgab578 crossref_primary_10_3389_fphar_2021_781379 crossref_primary_10_1177_00185787231151861 crossref_primary_10_1016_j_diabres_2022_110200 crossref_primary_10_3389_fendo_2024_1451100 crossref_primary_10_1007_s13300_021_01065_3 crossref_primary_10_1016_j_metabol_2021_154937 crossref_primary_10_1111_dom_15465 crossref_primary_10_2147_DMSO_S471535 crossref_primary_10_7759_cureus_46510 crossref_primary_10_1111_jdi_13764 crossref_primary_10_1186_s12916_021_02221_z crossref_primary_10_2337_ds20_0067 crossref_primary_10_1016_j_jcte_2024_100370 crossref_primary_10_1002_clc_23853 crossref_primary_10_21215_kjfp_2022_12_2_61 crossref_primary_10_3390_cancers14092072 crossref_primary_10_1177_11795514221074663 crossref_primary_10_3390_cancers13143473 crossref_primary_10_3390_ph14040364 crossref_primary_10_1007_s11428_022_00929_x crossref_primary_10_2337_cd21_0009 crossref_primary_10_2217_fca_2020_0210 crossref_primary_10_3389_fbioe_2022_876672 crossref_primary_10_3389_fsurg_2022_828649 crossref_primary_10_3390_jcm11010137 crossref_primary_10_1007_s13300_022_01262_8 crossref_primary_10_1038_s41746_024_01230_5 crossref_primary_10_5348_100073Z09HW2023CS crossref_primary_10_1111_jdi_13634 crossref_primary_10_1016_S2213_8587_22_00070_5 crossref_primary_10_1111_jdi_13753 crossref_primary_10_1136_pn_2022_003395 crossref_primary_10_14341_DM12848 crossref_primary_10_1111_jdi_13870 crossref_primary_10_7759_cureus_31437 crossref_primary_10_1007_s11606_021_07331_1 crossref_primary_10_1016_j_diabres_2021_109036 crossref_primary_10_1186_s12902_022_01139_8 crossref_primary_10_2147_CEOR_S361886 crossref_primary_10_2337_dc21_1800 crossref_primary_10_1093_fampra_cmac092 crossref_primary_10_3390_biomedicines11112976 crossref_primary_10_1136_ebmental_2021_300291 crossref_primary_10_2337_dc21_1929 crossref_primary_10_3390_ph14090899 crossref_primary_10_1111_jdi_13818 crossref_primary_10_1136_bmjnph_2023_000733 crossref_primary_10_3390_jcm11144193 crossref_primary_10_1016_j_ijcard_2022_06_027 crossref_primary_10_1016_j_lana_2021_100111 crossref_primary_10_3389_fcdhc_2023_1293926 crossref_primary_10_3390_biology10020155 crossref_primary_10_1016_j_mmm_2021_10_001 crossref_primary_10_1186_s12933_021_01400_9 crossref_primary_10_1016_j_diabres_2021_109146 crossref_primary_10_3390_ijms232214186 crossref_primary_10_1111_bcp_15100 crossref_primary_10_3390_biomedicines12010099 crossref_primary_10_1111_ijn_13012 crossref_primary_10_33678_cor_2021_108 crossref_primary_10_3389_fnut_2022_1035439 crossref_primary_10_1111_bcp_15348 crossref_primary_10_3390_clinpract11020031 crossref_primary_10_3390_jcm11237094 crossref_primary_10_52586_S563 crossref_primary_10_7326_L21_0707 crossref_primary_10_1136_bmj_n1171 crossref_primary_10_4236_wjcd_2023_133012 crossref_primary_10_1038_s41391_024_00793_4 crossref_primary_10_1136_bmjopen_2022_060852 crossref_primary_10_1016_j_scib_2022_08_002 crossref_primary_10_1055_a_1502_4925 crossref_primary_10_2337_dc22_1655 crossref_primary_10_2147_DMSO_S297913 crossref_primary_10_1007_s13300_025_01718_7 crossref_primary_10_1007_s40801_022_00309_3 crossref_primary_10_3390_jpm14010074 crossref_primary_10_1186_s12933_021_01326_2 crossref_primary_10_1001_jamanetworkopen_2024_0427 crossref_primary_10_1038_s41581_021_00519_y crossref_primary_10_1002_cpdd_1187 crossref_primary_10_3390_biom12020272 crossref_primary_10_1136_bmjdrc_2021_002636 crossref_primary_10_1016_j_coph_2021_09_001 crossref_primary_10_1007_s13300_023_01437_x crossref_primary_10_1186_s12875_022_01663_5 crossref_primary_10_1177_10105395221122643 crossref_primary_10_2337_cd21_0043 crossref_primary_10_1080_14740338_2022_2043848 crossref_primary_10_1016_j_diabres_2021_109123 crossref_primary_10_1007_s00772_021_00855_0 crossref_primary_10_1016_j_pcd_2023_07_006 crossref_primary_10_1155_2022_5603864 crossref_primary_10_3390_medicina58101475 crossref_primary_10_1002_jac5_1626 crossref_primary_10_1016_j_ijmedinf_2025_105801 crossref_primary_10_1161_HYPERTENSIONAHA_121_17323 crossref_primary_10_1016_j_jacc_2022_02_010 crossref_primary_10_1080_17434440_2021_1992274 crossref_primary_10_1016_j_jsps_2024_102054 crossref_primary_10_4239_wjd_v12_i9_1426 crossref_primary_10_1007_s00125_023_05950_3 crossref_primary_10_1007_s13300_021_01188_7 crossref_primary_10_1016_j_jdiacomp_2021_108110 crossref_primary_10_1111_dom_15038 crossref_primary_10_1177_2042018821997320 crossref_primary_10_14341_DM12803 crossref_primary_10_2337_cd21_0056 crossref_primary_10_1007_s13300_021_01165_0 crossref_primary_10_2147_CPAA_S288846 crossref_primary_10_1016_j_numecd_2021_08_039 crossref_primary_10_1002_hep_32742 crossref_primary_10_14341_DM12809 crossref_primary_10_3390_life12070998 |
| Cites_doi | 10.2337/dc14-0990 10.1111/dom.14100 10.1111/j.1742-1241.2012.02911.x 10.2337/dci18-0019 10.2337/dc15-2399 10.1503/cmaj.081041 10.2337/dc16-1957 10.1016/j.jdiacomp.2017.11.001 10.1111/dom.12438 10.1016/j.mayocp.2014.12.014 10.2337/dc12-1333 10.1016/S2213-8587(17)30194-8 10.2337/diacare.26.11.3080 10.2337/cd19-0061 10.2337/dc14-3053 10.1089/dia.2016.0421 10.2337/dci19-0066 10.1001/jama.2017.7117 10.7326/0003-4819-157-5-201209040-00508 10.1111/dom.12532 10.1111/j.1463-1326.2008.00934.x 10.1111/dom.12805 10.7326/M20-0864 10.2337/dc12-1205 10.1111/1753-0407.12060 10.2337/dc05-1365 10.1016/S2213-8587(13)70090-1 10.1001/jama.289.17.2254 10.1007/s00125-005-0132-0 10.1016/j.diabres.2016.10.022 10.1016/S2213-8587(19)30184-6 10.1016/S2213-8587(17)30308-X 10.1002/dmrr.2983 10.2337/db06-0653 10.2337/dc15-0249 10.2337/dc06-0042 10.2337/dci18-0033 10.2337/dcS15-3007 10.1016/j.diabres.2008.04.007 10.1056/NEJMoa1303576 10.1001/jama.2016.11708 10.2337/dc16-1771 10.1016/S0140-6736(10)60406-0 10.2337/dc09-2011 10.1016/S0140-6736(19)31271-1 10.1016/S2213-8587(17)30085-2 10.2337/dc14-1625 10.1016/j.mayocp.2016.06.010 10.1089/dia.2018.0200 10.1111/dom.12472 10.4158/EP09117.ORR 10.1111/dom.12417 10.2337/dci18-0012 10.1111/dom.12233 10.2337/dc18-1749 10.1136/bmj.j1321 10.1111/dom.12804 10.4158/EP15959.OR 10.2337/dc15-0100 10.1002/cpt.1307 10.1016/S0140-6736(19)32131-2 10.2337/dc14-0876 10.2337/dc15-0075 10.7326/0003-4819-154-9-201105030-00336 10.1097/MLR.0000000000000565 10.1016/S2213-8587(13)70144-X 10.1136/bmj.g5459 10.1016/j.ecl.2012.03.001 10.1001/jama.2017.7115 10.1210/jc.2015-3754 10.1111/j.1464-5491.2007.02407.x 10.2337/dc14-0649 10.1056/NEJMoa1615692 10.1001/jama.287.19.2563 10.1016/S0140-6736(18)31947-0 10.1111/dme.12303 10.1111/j.1463-1326.2009.01060.x 10.1111/j.1464-5491.2004.01319.x 10.1016/S0140-6736(14)61335-0 10.1056/NEJMoa0806470 10.1177/193229681300700617 10.1056/NEJMoa052187 10.7326/M15-2650 10.1111/dom.12618 10.1007/s13300-017-0282-3 10.1016/j.diabres.2018.06.016 10.1001/jamainternmed.2014.2894 10.2147/DMSO.S130834 |
| ContentType | Journal Article |
| Copyright | Copyright American Diabetes Association Jan 1, 2021 2020 by the American Diabetes Association. |
| Copyright_xml | – notice: Copyright American Diabetes Association Jan 1, 2021 – notice: 2020 by the American Diabetes Association. |
| CorporateAuthor | American Diabetes Association |
| CorporateAuthor_xml | – name: American Diabetes Association |
| DBID | AAYXX CITATION K9. NAPCQ 7X8 |
| DOI | 10.2337/dc21-S009 |
| DatabaseName | CrossRef ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitle | CrossRef ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic ProQuest Health & Medical Complete (Alumni) CrossRef |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1935-5548 |
| EndPage | S124 |
| ExternalDocumentID | 10_2337_dc21_S009 |
| GroupedDBID | --- -ET ..I .XZ 08P 0R~ 18M 29F 2WC 4.4 53G 5GY 5RE 5RS 5VS 6PF 8R4 8R5 AAFWJ AAIKC AAMNW AAWTL AAYEP AAYXX ABOCM ABPPZ ACGFO ACGOD ADBBV AEGXH AENEX AERZD AFOSN AFRAH AHMBA AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS BAWUL BENPR BTFSW CITATION CS3 DIK DU5 E3Z EBS EDB EMOBN EX3 F5P GX1 H13 HZ~ IAO IEA IHR INH INR IOF IPO KQ8 L7B M0K M5~ O5R O5S O9- OK1 OVD P2P PCD Q2X RHI SV3 TDI TEORI TR2 TWZ VVN W8F WH7 WOQ WOW YHG YOC ZCG ~KM K9. NAPCQ 7X8 |
| ID | FETCH-LOGICAL-c286t-b9548693ce73935154edab7dc4873c58cf9040b3e349a2ed5d43af7f1d98eb3a3 |
| ISSN | 0149-5992 1935-5548 |
| IngestDate | Thu Jul 10 23:14:32 EDT 2025 Mon Jun 30 16:56:48 EDT 2025 Thu Apr 24 23:01:15 EDT 2025 Tue Jul 01 04:12:02 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | Supplement_1 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c286t-b9548693ce73935154edab7dc4873c58cf9040b3e349a2ed5d43af7f1d98eb3a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| PQID | 2486190574 |
| PQPubID | 47715 |
| ParticipantIDs | proquest_miscellaneous_2469094597 proquest_journals_2486190574 crossref_primary_10_2337_dc21_S009 crossref_citationtrail_10_2337_dc21_S009 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-01-01 |
| PublicationDateYYYYMMDD | 2021-01-01 |
| PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Alexandria |
| PublicationPlace_xml | – name: Alexandria |
| PublicationTitle | Diabetes care |
| PublicationYear | 2021 |
| Publisher | American Diabetes Association |
| Publisher_xml | – name: American Diabetes Association |
| References | Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2022031220385391100_B3) 2016; 39 Holman (2022031220385391100_B37) 2008; 359 Riddle (2022031220385391100_B90) 2015; 17 Babu (2022031220385391100_B43) 2009; 15 Bode (2022031220385391100_B8) 2015; 38 Bolli (2022031220385391100_B76) 2015; 17 Bergenstal (2022031220385391100_B14) 2013; 369 Cahn (2022031220385391100_B44) 2016; 39 Bartley (2022031220385391100_B6) 2008; 25 Akturk (2022031220385391100_B92) 2018; 20 Heller (2022031220385391100_B88) 2013; 5 Rodbard (2022031220385391100_B80) 2013; 30 Lane (2022031220385391100_B10) 2017; 318 Zinman (2022031220385391100_B82) 2012; 35 Mannucci (2022031220385391100_B87) 2009; 11 Wysham (2022031220385391100_B89) 2016; 22 Out (2022031220385391100_B40) 2018; 32 Rodbard (2022031220385391100_B96) 2014; 2 Yki-Järvinen (2022031220385391100_B78) 2015; 17 Cleary (2022031220385391100_B1) 2006; 55 Yki-Järvinen (2022031220385391100_B75) 2006; 49 Levin (2022031220385391100_B55) 2017; 10 Dandona (2022031220385391100_B32) 2017; 5 Eng (2022031220385391100_B94) 2014; 384 Owens (2022031220385391100_B72) 2017; 124 Brown (2022031220385391100_B19) 2019 2022031220385391100_B62 2022031220385391100_B63 Wang (2022031220385391100_B31) 2017; 8 Davies (2022031220385391100_B59) 2013; 36 Abdul-Ghani (2022031220385391100_B45) 2015; 17 Hermansen (2022031220385391100_B74) 2006; 29 Davies (2022031220385391100_B35) 2018; 41 Cowart (2022031220385391100_B84) 2020; 38 Klaff (2022031220385391100_B9a) 2020; 22 Aroda (2022031220385391100_B41) 2016; 101 Tauschmann (2022031220385391100_B18) 2018; 392 Garg (2022031220385391100_B17) 2017; 19 Riddle (2022031220385391100_B61) 2018; 41 Henry (2022031220385391100_B42) 2012; 66 Horvath (2022031220385391100_B70) 2007 Maruthur (2022031220385391100_B38) 2016; 164 Riddle (2022031220385391100_B73) 2003; 26 Porcellati (2022031220385391100_B67) 2015; 38 Bell (2022031220385391100_B22) 2014; 2 Kang (2022031220385391100_B64) 2018; 143 Wang (2022031220385391100_B68) 2010; 33 Petrie (2022031220385391100_B30) 2017; 5 2022031220385391100_B48 Buse (2022031220385391100_B36) 2020; 43 Nathan (2022031220385391100_B2) 2005; 353 Chiang (2022031220385391100_B21) 2014 Yeh (2022031220385391100_B12) 2012; 157 Bergenstal (2022031220385391100_B16) 2016; 316 Singh (2022031220385391100_B54) 2017; 19 Ratner (2022031220385391100_B27) 2004; 21 Bennett (2022031220385391100_B49) 2011; 154 Monami (2022031220385391100_B71) 2008; 81 Pickup (2022031220385391100_B13) 2013; 7 Home (2022031220385391100_B11) 2015; 38 Maiorino (2022031220385391100_B95) 2017; 40 Phung (2022031220385391100_B46) 2014; 16 Abd El Aziz (2022031220385391100_B56) 2017; 19 Patel (2022031220385391100_B65) 2016; 54 Tricco (2022031220385391100_B5) 2014; 349 Frid (2022031220385391100_B25) 2016; 91 Aroda (2022031220385391100_B58) 2017; 5 Diamant (2022031220385391100_B60) 2010; 375 Russell-Jones (2022031220385391100_B9) 2017; 40 Aroda (2022031220385391100_B47) 2019; 7 Cefalu (2022031220385391100_B85) 2018; 41 Maloney (2022031220385391100_B50) 2019; 105 Rosenstock (2022031220385391100_B33) 2018; 41 Vaz (2022031220385391100_B23) 2018; 62 McCall (2022031220385391100_B86) 2012; 41 Diamant (2022031220385391100_B93) 2014; 37 Peters (2022031220385391100_B20) 2013 Pratley (2022031220385391100_B53) 2019; 394 Vijan (2022031220385391100_B51) 2014; 174 Meng (2022031220385391100_B29) 2018; 34 Blevins (2022031220385391100_B9b) Buckingham (2022031220385391100_B15) 2015; 38 Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2022031220385391100_B4) 2002; 287 Singh (2022031220385391100_B69) 2009; 180 Terauchi (2022031220385391100_B77) 2016; 18 Edelman (2022031220385391100_B28) 2006; 29 Blonde (2022031220385391100_B66) 2009; 11 Tsapas (2022031220385391100_B52) 2020; 173 Marso (2022031220385391100_B79) 2017 Wysham (2022031220385391100_B81) 2017; 318 DeWitt (2022031220385391100_B7) 2003; 289 Lipska (2022031220385391100_B83) 2018 Yki-Järvinen (2022031220385391100_B91) 2014; 37 Bergenstal (2022031220385391100_B26) 2015; 90 Giorgino (2022031220385391100_B57) 2015; 38 2022031220385391100_B39 2022031220385391100_B34 Bell (2022031220385391100_B24) 2015; 38 |
| References_xml | – volume: 37 start-page: 3235 year: 2014 ident: 2022031220385391100_B91 article-title: New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2) publication-title: Diabetes Care doi: 10.2337/dc14-0990 – year: 2019 ident: 2022031220385391100_B19 – volume: 22 start-page: 1799 year: 2020 ident: 2022031220385391100_B9a article-title: Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: results from the 26-week PRONTO-T1D study publication-title: Diabetes Obes Metab doi: 10.1111/dom.14100 – volume: 66 start-page: 446 year: 2012 ident: 2022031220385391100_B42 article-title: Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial publication-title: Int J Clin Pract doi: 10.1111/j.1742-1241.2012.02911.x – volume: 41 start-page: 1299 year: 2018 ident: 2022031220385391100_B85 article-title: Insulin Access and Affordability Working Group: conclusions and recommendations publication-title: Diabetes Care doi: 10.2337/dci18-0019 – volume: 39 start-page: 1378 year: 2016 ident: 2022031220385391100_B3 article-title: Mortality in type 1 diabetes in the DCCT/EDIC versus the general population publication-title: Diabetes Care doi: 10.2337/dc15-2399 – volume: 180 start-page: 385 year: 2009 ident: 2022031220385391100_B69 article-title: Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis publication-title: CMAJ doi: 10.1503/cmaj.081041 – volume: 40 start-page: 614 year: 2017 ident: 2022031220385391100_B95 article-title: Insulin and glucagon-like peptide 1 receptor agonist combination therapy in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials publication-title: Diabetes Care doi: 10.2337/dc16-1957 – volume: 32 start-page: 171 year: 2018 ident: 2022031220385391100_B40 article-title: Long-term treatment with metformin in type 2 diabetes and methylmalonic acid: post hoc analysis of a randomized controlled 4.3 year trial publication-title: J Diabetes Complications doi: 10.1016/j.jdiacomp.2017.11.001 – volume: 17 start-page: 386 year: 2015 ident: 2022031220385391100_B76 article-title: New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3) publication-title: Diabetes Obes Metab doi: 10.1111/dom.12438 – volume: 90 start-page: 329 year: 2015 ident: 2022031220385391100_B26 article-title: Safety and efficacy of insulin therapy delivered via a 4mm pen needle in obese patients with diabetes publication-title: Mayo Clin Proc doi: 10.1016/j.mayocp.2014.12.014 – volume: 36 start-page: 1368 year: 2013 ident: 2022031220385391100_B59 article-title: Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas publication-title: Diabetes Care doi: 10.2337/dc12-1333 – volume: 5 start-page: 597 year: 2017 ident: 2022031220385391100_B30 article-title: Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(17)30194-8 – volume: 26 start-page: 3080 year: 2003 ident: 2022031220385391100_B73 article-title: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients publication-title: Diabetes Care doi: 10.2337/diacare.26.11.3080 – volume: 38 start-page: 304 year: 2020 ident: 2022031220385391100_B84 article-title: Overbasalization: addressing hesitancy in treatment intensification beyond basal insulin publication-title: Clin Diabetes doi: 10.2337/cd19-0061 – volume: 38 start-page: 1197 year: 2015 ident: 2022031220385391100_B15 article-title: Predictive low-glucose insulin suspension reduces duration of nocturnal hypoglycemia in children without increasing ketosis publication-title: Diabetes Care doi: 10.2337/dc14-3053 – volume: 19 start-page: 155 year: 2017 ident: 2022031220385391100_B17 article-title: Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes publication-title: Diabetes Technol Ther doi: 10.1089/dia.2016.0421 – volume: 43 start-page: 487 year: 2020 ident: 2022031220385391100_B36 article-title: 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) publication-title: Diabetes Care doi: 10.2337/dci19-0066 – volume: 318 start-page: 45 year: 2017 ident: 2022031220385391100_B81 article-title: Effect of insulin degludec vs insulin glargine u100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2017.7117 – volume: 157 start-page: 336 year: 2012 ident: 2022031220385391100_B12 article-title: Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis publication-title: Ann Intern Med doi: 10.7326/0003-4819-157-5-201209040-00508 – volume: 17 start-page: 1142 year: 2015 ident: 2022031220385391100_B78 article-title: Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension publication-title: Diabetes Obes Metab doi: 10.1111/dom.12532 – volume: 11 start-page: 53 year: 2009 ident: 2022031220385391100_B87 article-title: Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis publication-title: Diabetes Obes Metab doi: 10.1111/j.1463-1326.2008.00934.x – volume: 19 start-page: 228 year: 2017 ident: 2022031220385391100_B54 article-title: Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis publication-title: Diabetes Obes Metab doi: 10.1111/dom.12805 – volume: 173 start-page: 278 year: 2020 ident: 2022031220385391100_B52 article-title: Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis publication-title: Ann Intern Med doi: 10.7326/M20-0864 – volume: 35 start-page: 2464 year: 2012 ident: 2022031220385391100_B82 article-title: Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long) publication-title: Diabetes Care doi: 10.2337/dc12-1205 – volume: 5 start-page: 482 year: 2013 ident: 2022031220385391100_B88 article-title: Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the treatment of diabetes mellitus publication-title: J Diabetes doi: 10.1111/1753-0407.12060 – volume: 29 start-page: 1269 year: 2006 ident: 2022031220385391100_B74 article-title: A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes publication-title: Diabetes Care doi: 10.2337/dc05-1365 – volume: 2 start-page: 30 year: 2014 ident: 2022031220385391100_B96 article-title: Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(13)70090-1 – ident: 2022031220385391100_B9b article-title: PRONTO-T2D Investigators. Randomized double-blind clinical trial comparing ultra rapid lispro with lispro in a basal-bolus regimen in patients with type 2 diabetes: PRONTO-T2D – volume: 289 start-page: 2254 year: 2003 ident: 2022031220385391100_B7 article-title: Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review publication-title: JAMA doi: 10.1001/jama.289.17.2254 – volume: 49 start-page: 442 year: 2006 ident: 2022031220385391100_B75 article-title: Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study publication-title: Diabetologia doi: 10.1007/s00125-005-0132-0 – volume: 124 start-page: 57 year: 2017 ident: 2022031220385391100_B72 article-title: Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy publication-title: Diabetes Res Clin Pract doi: 10.1016/j.diabres.2016.10.022 – volume: 7 start-page: 596 year: 2019 ident: 2022031220385391100_B47 article-title: Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(19)30184-6 – volume: 5 start-page: 864 year: 2017 ident: 2022031220385391100_B32 article-title: Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(17)30308-X – start-page: 53 volume-title: JAMA year: 2018 ident: 2022031220385391100_B83 article-title: Association of initiation of basal insulin analogs vs neutral protamine hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes – ident: 2022031220385391100_B62 – volume: 34 start-page: e2983 year: 2018 ident: 2022031220385391100_B29 article-title: Effect of metformin on glycaemic control in patients with type 1 diabetes: a meta-analysis of randomized controlled trials publication-title: Diabetes Metab Res Rev doi: 10.1002/dmrr.2983 – volume: 55 start-page: 3556 year: 2006 ident: 2022031220385391100_B1 article-title: The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study publication-title: Diabetes doi: 10.2337/db06-0653 – volume: 38 start-page: 2217 year: 2015 ident: 2022031220385391100_B11 article-title: New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4) publication-title: Diabetes Care doi: 10.2337/dc15-0249 – volume: 29 start-page: 2189 year: 2006 ident: 2022031220385391100_B28 article-title: A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes publication-title: Diabetes Care doi: 10.2337/dc06-0042 – volume: 41 start-page: 2669 year: 2018 ident: 2022031220385391100_B35 article-title: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) publication-title: Diabetes Care doi: 10.2337/dci18-0033 – volume: 39 start-page: S137 year: 2016 ident: 2022031220385391100_B44 article-title: Clinical considerations for use of initial combination therapy in type 2 diabetes publication-title: Diabetes Care doi: 10.2337/dcS15-3007 – volume: 81 start-page: 184 year: 2008 ident: 2022031220385391100_B71 article-title: Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis publication-title: Diabetes Res Clin Pract doi: 10.1016/j.diabres.2008.04.007 – volume: 369 start-page: 224 year: 2013 ident: 2022031220385391100_B14 article-title: Threshold-based insulin-pump interruption for reduction of hypoglycemia publication-title: N Engl J Med doi: 10.1056/NEJMoa1303576 – volume: 316 start-page: 1407 year: 2016 ident: 2022031220385391100_B16 article-title: Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes publication-title: JAMA doi: 10.1001/jama.2016.11708 – volume: 40 start-page: 943 year: 2017 ident: 2022031220385391100_B9 article-title: Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1) publication-title: Diabetes Care doi: 10.2337/dc16-1771 – volume: 375 start-page: 2234 year: 2010 ident: 2022031220385391100_B60 article-title: Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial publication-title: Lancet doi: 10.1016/S0140-6736(10)60406-0 – volume-title: Diabetes Care year: 2014 ident: 2022031220385391100_B21 article-title: Type 1 diabetes through the life span: a position statement of the American Diabetes Association – volume: 33 start-page: 1555 year: 2010 ident: 2022031220385391100_B68 article-title: Dose-response effects of insulin glargine in type 2 diabetes publication-title: Diabetes Care doi: 10.2337/dc09-2011 – ident: 2022031220385391100_B63 – volume: 394 start-page: 39 year: 2019 ident: 2022031220385391100_B53 article-title: Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial publication-title: Lancet doi: 10.1016/S0140-6736(19)31271-1 – volume: 5 start-page: 355 year: 2017 ident: 2022031220385391100_B58 article-title: Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(17)30085-2 – volume: 38 start-page: 2241 year: 2015 ident: 2022031220385391100_B57 article-title: Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2) publication-title: Diabetes Care doi: 10.2337/dc14-1625 – volume: 91 start-page: 1231 year: 2016 ident: 2022031220385391100_B25 article-title: New insulin delivery recommendations publication-title: Mayo Clin Proc doi: 10.1016/j.mayocp.2016.06.010 – volume: 20 start-page: 639 year: 2018 ident: 2022031220385391100_B92 article-title: Improved postprandial glucose with inhaled technosphere insulin compared with insulin aspart in patients with type 1 diabetes on multiple daily injections: the STAT study publication-title: Diabetes Technol Ther doi: 10.1089/dia.2018.0200 – volume: 17 start-page: 835 year: 2015 ident: 2022031220385391100_B90 article-title: One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension publication-title: Diabetes Obes Metab doi: 10.1111/dom.12472 – volume: 15 start-page: 696 year: 2009 ident: 2022031220385391100_B43 article-title: Safe and simple emergency department discharge therapy for patients with type 2 diabetes mellitus and severe hyperglycemia publication-title: Endocr Pract doi: 10.4158/EP09117.ORR – volume: 17 start-page: 268 year: 2015 ident: 2022031220385391100_B45 article-title: Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial publication-title: Diabetes Obes Metab doi: 10.1111/dom.12417 – volume: 41 start-page: 929 year: 2018 ident: 2022031220385391100_B61 article-title: The cost of diabetes care—an elephant in the room publication-title: Diabetes Care doi: 10.2337/dci18-0012 – volume-title: American Diabetes Association/JDRF Type 1 Diabetes Sourcebook year: 2013 ident: 2022031220385391100_B20 – volume: 16 start-page: 410 year: 2014 ident: 2022031220385391100_B46 article-title: Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis publication-title: Diabetes Obes Metab doi: 10.1111/dom.12233 – volume: 41 start-page: 2560 year: 2018 ident: 2022031220385391100_B33 article-title: Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials publication-title: Diabetes Care doi: 10.2337/dc18-1749 – ident: 2022031220385391100_B34 doi: 10.1136/bmj.j1321 – ident: 2022031220385391100_B39 – volume: 19 start-page: 216 year: 2017 ident: 2022031220385391100_B56 article-title: A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients publication-title: Diabetes Obes Metab doi: 10.1111/dom.12804 – volume: 22 start-page: 653 year: 2016 ident: 2022031220385391100_B89 article-title: Effect of total daily dose on efficacy, dosing, and safety of 2 dose titration regimens of human regular U500 insulin in severely insulin-resistant patients with type 2 diabetes publication-title: Endocr Pract doi: 10.4158/EP15959.OR – volume: 38 start-page: 1008 year: 2015 ident: 2022031220385391100_B24 article-title: Impact of fat, protein, and glycemic index on postprandial glucose control in type 1 diabetes: implications for intensive diabetes management in the continuous glucose monitoring era publication-title: Diabetes Care doi: 10.2337/dc15-0100 – volume: 105 start-page: 1213 year: 2019 ident: 2022031220385391100_B50 article-title: A model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes: comparison of treatment effects at therapeutic doses publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.1307 – ident: 2022031220385391100_B48 doi: 10.1016/S0140-6736(19)32131-2 – volume: 37 start-page: 2763 year: 2014 ident: 2022031220385391100_B93 article-title: Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes publication-title: Diabetes Care doi: 10.2337/dc14-0876 – volume: 38 start-page: 2266 year: 2015 ident: 2022031220385391100_B8 article-title: Inhaled technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial publication-title: Diabetes Care doi: 10.2337/dc15-0075 – volume: 154 start-page: 602 year: 2011 ident: 2022031220385391100_B49 article-title: Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations publication-title: Ann Intern Med doi: 10.7326/0003-4819-154-9-201105030-00336 – volume: 54 start-page: 796 year: 2016 ident: 2022031220385391100_B65 article-title: Social determinants of health, cost-related nonadherence, and cost-reducing behaviors among adults with diabetes: findings from the National Health Interview Survey publication-title: Med Care doi: 10.1097/MLR.0000000000000565 – volume: 2 start-page: 133 year: 2014 ident: 2022031220385391100_B22 article-title: Efficacy of carbohydrate counting in type 1 diabetes: a systematic review and meta-analysis publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(13)70144-X – volume: 62 start-page: 337 year: 2018 ident: 2022031220385391100_B23 article-title: Effectiveness and safety of carbohydrate counting in the management of adult patients with type 1 diabetes mellitus: a systematic review and meta-analysis publication-title: Arch Endocrinol Metab – volume: 349 start-page: g5459 year: 2014 ident: 2022031220385391100_B5 article-title: Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis publication-title: BMJ doi: 10.1136/bmj.g5459 – volume: 41 start-page: 57 year: 2012 ident: 2022031220385391100_B86 article-title: Insulin therapy and hypoglycemia publication-title: Endocrinol Metab Clin North Am doi: 10.1016/j.ecl.2012.03.001 – volume: 318 start-page: 33 year: 2017 ident: 2022031220385391100_B10 article-title: Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2017.7115 – volume: 101 start-page: 1754 year: 2016 ident: 2022031220385391100_B41 article-title: Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2015-3754 – volume: 25 start-page: 442 year: 2008 ident: 2022031220385391100_B6 article-title: Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial publication-title: Diabet Med doi: 10.1111/j.1464-5491.2007.02407.x – volume: 38 start-page: 503 year: 2015 ident: 2022031220385391100_B67 article-title: Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes publication-title: Diabetes Care doi: 10.2337/dc14-0649 – volume-title: N Engl J Med year: 2017 ident: 2022031220385391100_B79 article-title: Efficacy and safety of degludec versus glargine in type 2 diabetes doi: 10.1056/NEJMoa1615692 – volume: 287 start-page: 2563 year: 2002 ident: 2022031220385391100_B4 article-title: Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus publication-title: JAMA doi: 10.1001/jama.287.19.2563 – volume: 392 start-page: 1321 year: 2018 ident: 2022031220385391100_B18 article-title: Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial publication-title: Lancet doi: 10.1016/S0140-6736(18)31947-0 – volume: 30 start-page: 1298 year: 2013 ident: 2022031220385391100_B80 article-title: Comparison of insulin degludec with insulin glargine in insulin-naive subjects with type 2 diabetes: a 2-year randomized, treat-to-target trial publication-title: Diabet Med doi: 10.1111/dme.12303 – volume: 11 start-page: 623 year: 2009 ident: 2022031220385391100_B66 article-title: Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study publication-title: Diabetes Obes Metab doi: 10.1111/j.1463-1326.2009.01060.x – volume: 21 start-page: 1204 year: 2004 ident: 2022031220385391100_B27 article-title: Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial publication-title: Diabet Med doi: 10.1111/j.1464-5491.2004.01319.x – volume: 384 start-page: 2228 year: 2014 ident: 2022031220385391100_B94 article-title: Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis publication-title: Lancet doi: 10.1016/S0140-6736(14)61335-0 – volume: 359 start-page: 1577 year: 2008 ident: 2022031220385391100_B37 article-title: 10-year follow-up of intensive glucose control in type 2 diabetes publication-title: N Engl J Med doi: 10.1056/NEJMoa0806470 – volume: 7 start-page: 1567 year: 2013 ident: 2022031220385391100_B13 article-title: The evidence base for diabetes technology: appropriate and inappropriate meta-analysis publication-title: J Diabetes Sci Technol doi: 10.1177/193229681300700617 – volume: 353 start-page: 2643 year: 2005 ident: 2022031220385391100_B2 article-title: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes publication-title: N Engl J Med doi: 10.1056/NEJMoa052187 – volume: 164 start-page: 740 year: 2016 ident: 2022031220385391100_B38 article-title: Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis publication-title: Ann Intern Med doi: 10.7326/M15-2650 – volume: 18 start-page: 366 year: 2016 ident: 2022031220385391100_B77 article-title: New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2) publication-title: Diabetes Obes Metab doi: 10.1111/dom.12618 – volume: 8 start-page: 727 year: 2017 ident: 2022031220385391100_B31 article-title: Effects of insulin plus glucagon-like peptide-1 receptor agonists (GLP-1RAs) in treating type 1 diabetes mellitus: a systematic review and meta-analysis publication-title: Diabetes Ther doi: 10.1007/s13300-017-0282-3 – start-page: CD005613 issue: 2 year: 2007 ident: 2022031220385391100_B70 article-title: Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus publication-title: Cochrane Database Syst Rev – volume: 143 start-page: 24 year: 2018 ident: 2022031220385391100_B64 article-title: Cost-related medication non-adherence among U.S. adults with diabetes publication-title: Diabetes Res Clin Pract doi: 10.1016/j.diabres.2018.06.016 – volume: 174 start-page: 1227 year: 2014 ident: 2022031220385391100_B51 article-title: Effect of patients’ risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus publication-title: JAMA Intern Med doi: 10.1001/jamainternmed.2014.2894 – volume: 10 start-page: 123 year: 2017 ident: 2022031220385391100_B55 article-title: Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research publication-title: Diabetes Metab Syndr Obes doi: 10.2147/DMSO.S130834 |
| SSID | ssj0004488 |
| Score | 2.730163 |
| SecondaryResourceType | review_article |
| Snippet | The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA's current clinical practice recommendations and is intended to... The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to... |
| SourceID | proquest crossref |
| SourceType | Aggregation Database Enrichment Source Index Database |
| StartPage | S111 |
| SubjectTerms | Best practice Clinical medicine Diabetes Diabetes mellitus Disease management Drug therapy Glucose Health care Health services Professional practice Quality of care |
| Title | 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021 |
| URI | https://www.proquest.com/docview/2486190574 https://www.proquest.com/docview/2469094597 |
| Volume | 44 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS9xAEF-sgvSlWFvxqpZV-iCUXM9k87F9E1s9P1HuBF8kbGY3IEhOND7oX9-ZZLO5HCLVlxCSzd5lfpvZ387OB2M_QCWAs3Di4QAxntDCeBJXFp6OfFARakMwFOB8ehYNL8XRVXjVFmmtokvKrA_PL8aVvAdVvIa4UpTsG5B1neIFPEd88YgI4_G_MJb9n-dt6ukbIE5ZRUjVeRsObp-g8n0fN97ktP4fWeNB7f1i92koDIlMH9ZB5gEFUIcUN8S1uVGlsp42Ffg7M6YCtwfkHpkdAo2NUXqhlB0lKcSUlhtZBTmrfv2gCuDXgD89GgxkO8c0--rD3VF6_mc_PTk8O_7AFnzk9lR24vhiKsW7qIqFun9Rp4Oirn-5jrskojuHVsRgvMQ-WUbPd2t4PrM5UyyzxVPrs_CFXcs-76DEW5R4OeENStyh9Js7jPgk5xYjThjxm4J3MPrKLvf_jveGni1q4YGfRKWXUYa9SAZgKBchsklhtMpiDbhyDCBMIJf42WSBCYRUvtGhFoHK43xHy8RkgQpW2HwxKcwq4zG2gjyWkYqFgDBXyB610pAJfDjMwh7bbqSUgs34ToVHblNc-ZFAUxJoSgLtsS3X9K5Oc_JSo_VG1Kn9Ch5SH98GSWUYix7bdLdRR9HGkyrM5JHaRHIgBa5dv73exRr72I7bdTZf3j-aDSR9Zfa9GiT_AGOvWIc |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=9.+Pharmacologic+Approaches+to+Glycemic+Treatment%3A+Standards+of+Medical+Care+in+Diabetes-2021&rft.jtitle=Diabetes+care&rft.date=2021-01-01&rft.pub=American+Diabetes+Association&rft.issn=0149-5992&rft.volume=44&rft.spage=S111&rft_id=info:doi/10.2337%2Fdc21-S009&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0149-5992&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0149-5992&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0149-5992&client=summon |